Andrew Vaillant | Chief Scientific Officer
Replicor Inc.

Andrew Vaillant, Chief Scientific Officer, Replicor Inc.

Dr. Vaillant is the Chief Scientific Officer at Replicor Inc.  He has more than 20 years of experience in the fields of nucleic acid chemistry, virology and drug development and is the discoverer of Replicor’s nucleic acid polymer (NAP) technology.  Dr. Vaillant has authored numerous primary publications and reviews on the use of NAPs in various infectious diseases focusing on HBV and HDV and the role of HBsAg loss and transaminase flares in achieving a functional cure of HBV.  He was a postdoctoral fellow at the Montreal Neurological Institute and holds a Ph.D. in Cell Biology from the University of Ottawa.


Day 2 - November 29 @ 14:30

Clinical updates for NAPs in HBV and HDV: multiyear follow-up from phase II studies and compassionate use in cirrhotic patients

Day 2 - November 29 @ 16:30

Panel: Toward a Hepatitis B-Free Future: Perspectives on Achieving a Functional Cure

  • How do you define a functional / partial cure – how should we use these terms and what are their limitations?

  • Which technologies/ modalities are we using to achieve a functional cure? What are the limits of different approaches? Can they be combined for more therapeutic benefit? (Antivirals, Antibodies, Vaccines, siRNA

  • Components to an effective cure strategy:

    o Use of viral replication inhibitors

    o Reducing viral surface antigen load – do we still have room to further reduce load?

    o Activation of antiviral immune response

  • Challenges in balancing side-effects and therapeutic efficacy

    How do we manage / avoid resistance


last published: 02/Jan/24 12:15 GMT

back to speakers